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The Genetic Basis of Cognitive 
impairment and Dementia in 
Parkinson’s Disease
Lucy M. Collins* and Caroline H. Williams-Gray
John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK
Cognitive dysfunction is a common feature of Parkinson’s disease (PD) with mild cogni-
tive impairment affecting around a quarter of patients in the early stages of their disease, 
and approximately half developing dementia by 10 years from diagnosis. However, the 
pattern of cognitive impairments and their speed of evolution vary markedly between 
individuals. While some of this variability may relate to extrinsic factors and comorbidi-
ties, inherited genetic heterogeneity is also known to play an important role. A number of 
common genetic variants have been identified, which contribute to cognitive function in 
PD, including variants in catechol-O-methyltransferase, microtubule-associated protein 
tau, and apolipoprotein E. Furthermore, rarer mutations in glucocerebrosidase and 
α-synuclein and are strongly associated with dementia risk in PD. This review explores 
the functional impact of these variants on cognition in PD and discusses how such gen-
otype–phenotype associations provide a window into the mechanistic basis of cognitive 
heterogeneity in this disorder. This has consequent implications for the development of 
much more targeted therapeutic strategies for cognitive symptoms in PD.
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iNTRODUCTiON
Parkinson’s disease (PD) is typically characterized as a movement disorder with the cardinal motor 
features of bradykinesia, rigidity, and rest tremor reflecting dysfunction within dopaminergic 
nigrostriatal circuitry. However, non-motor symptoms constitute a significant part of the symptom 
burden in PD, reflecting more widespread pathology throughout both the brain and the peripheral 
and enteric nervous systems. Among the most relevant of these non-motor symptoms in terms 
of quality of life and planning care requirements is cognitive dysfunction. This evolves through 
the course of the disease and dementia ensues in nearly 50% of PD patients by 10 years into their 
illness (1). The factors that underlie this evolution are not fully understood, but pathologically the 
dementing process seems to involve Lewy body deposition and Alzheimer’s type changes in cortical 
brain regions (2) as well as widespread cholinergic deficits (3).
Cognitive deficits in PD are heterogeneous in terms of the domains affected including executive 
dysfunction, memory, and visuospatial impairments. There is also considerable variation in the 
speed at which cognitive deficits develop, with some patients progressing rapidly to dementia while 
others have a slower course (1). To some extent, this course is predictable early on in the disease: in 
an incident population-representative PD cohort followed up for 10 years from diagnosis, patients 
who were older at diagnosis with more motor impairment and early dysfunction on neuropsycho-
logical tests with a posterior cortical basis (semantic fluency and pentagon copying) progressed 
FiGURe 1 | Schematic representation of the two distinct cognitive syndromes of Parkinson’s disease. “Frontal executive” impairments in early disease 
appear to be a consequence of a hyperdopaminergic state in the prefrontal cortex, which is in turn modulated by COMT genotype and dopaminergic medication. 
These deficits can get better or worse over time but are not associated global cognitive decline and dementia risk. In contrast, early deficits on more posterior 
cortically based cognitive tasks do not have a dopaminergic basis, but reflect the early stages of a dementing process due to Lewy body deposition and Alzheimer’s 
type changes in posterior cortical areas. This irreversible pathological process is influenced by early on by GBA mutations, MAPT H1/H2 haplotypes, and at a later 
disease stage by variation in APOE.
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more rapidly to dementia. In contrast, more frontostriatally based 
executive deficits were not associated with earlier dementia and, 
in fact, even improved in some patients as the disease progressed 
(1) (Figure  1). Similarly, verbal fluency and silhouette percep-
tion impairments preceded onset of dementia in an independent 
longitudinal study (4). Further support for the concept that 
posterior cortical dysfunction predicts dementia comes from 
neuroimaging studies with longitudinal follow-up demonstrat-
ing that hypometabolism (5) and atrophy (6) in posterior cortical 
regions precede cognitive decline.
Thus, mild cognitive impairment in PD (PD-MCI) per  se 
is not necessarily a prodrome of dementia: some individuals 
with PD-MCI remain cognitively stable over time and some 
revert back to normal cognitive function (7, 8). While cognitive 
phenotype is helpful in predicting prognosis in these “PD-MCI” 
cases as discussed above, knowledge of genetic variation may 
also be useful in this regard. The underlying genetic basis of PD 
is complex: a small proportion of PD cases are accounted for 
by monogenic forms of PD inherited in a Mendelian fashion 
(e.g., related to mutations in α-synuclein (SNCA), leucine-rich 
repeat kinase 2 (LRRK2), parkin, Parkinson’s disease-associated 
kinase-1 (PINK-1), DJ-1, ATP13A2), but numerous susceptibility 
genes and loci have also been identified (at least 24) (9), which 
contribute to the risk of idiopathic PD. In this article, we will 
review how this complex genetic heterogeneity maps onto phe-
notypic cognitive heterogeneity of PD. We will first discuss the 
cognitive characteristics of Mendelian forms of PD. We will then 
focus on two PD susceptibility genes, namely, glucocerebrosidase 
(GBA) and microtubule-associated protein tau (MAPT), both of 
which influence progression to dementia in PD. Finally, we will 
discuss candidate genes implicated in modulating cognition in 
PD but not associated with increased risk of development of PD 
per se. These include catechol-O-methyltransferase (COMT) and 
apolipoprotein E (APOE). A better understanding of these genetic 
influences on cognition in PD will lead to improved patient strati-
fication and could guide novel therapeutic strategies for cognitive 
dysfunction in PD, better targeted at the most relevant underlying 
pathogenic pathways.
iNSiGHTS FROM MONOGeNiC 
PARKiNSON’S DiSeASe
Although most cases of PD are idiopathic, 3–5% of cases are caused 
by a single gene variant (10). Genes associated with autosomal 
dominantly inherited PD include SNCA (11–13) and LRRK2 (14, 
15), and more recently eukaryotic translation initiation factor 4 
gamma-1 (EIF4G1) (16) and vacuolar protein sorting-associated 
protein 35 (VPS35) (17) have been identified. Autosomal reces-
sive forms of PD are associated with mutations in Parkin (Parkin 
E3 ubiquitin ligase) (18), PINK-1 (19), DJ-1 (PARK7, Parkinson 
protein 7) (20). These different genetic forms of PD vary in their 
clinical and cognitive phenotypes (see Table 1).
TABLe 1 | Monogenic PD genes.
Clinical phenotype Associated neuropathology Reference
AUTOSOMAL DOMiNANT
SNCA Early onset rapidly progressive parkinsonism with dementia,  
behavioral impairments, autonomic dysfunction
Widespread Lewy body pathology in brainstem and cortex; 
neuronal loss in hippocampus
(11, 12, 
21–23)
LRRK2 Similar to idiopathic PD, but dementia less common Nigrostriatal degeneration ± cortical involvement; Lewy bodies in 
most with G2019S mutation, often absent with rarer mutations
(14, 15, 
24–28)
EIF4G1 Late onset slowly progressive DOPA responsive parkinsonism with 
preserved cognition
Lewy body pathology in brainstem and cortex (16)
VPS35 Tremor dominant DOPA responsive parkinsonism, variable cognitive, 
and behavioral features
Pathology uncertain (17, 29)
AUTOSOMAL ReCeSSive
Parkin Early onset DOPA responsive parkinsonism with dystonia and diurnal 
fluctuation, slow progression, no/minimal cognitive impairment
Nigrostriatal degeneration, minimal cortical involvement, no Lewy 
bodies
(18, 30, 31)
PINK1 Early onset slowly progressive DOPA responsive 
parkinsonism ± affective and psychiatric symptoms
Lewy pathology and neuronal loss in the substantia nigra pars 
compacta, but sparing the locus coeruleus (1 case)
(19, 24, 32, 
33)
DJ1 Early onset slowly progressive DOPA responsive parkinsonism,  
no/minimal cognitive impairment
Pathology uncertain (20)
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Some of these genotype–phenotype associations are very well 
established and provide useful insights into pathogenesis. For 
example, monogenic forms of PD caused by mutations within, 
or a change in dose of, the SNCA gene implicate α-synuclein in 
the development of dementia in PD. SNCA mutations, including 
A53T, A30P, and E46K, are often associated with an early onset 
severe clinical phenotype with cognitive decline and behavioral 
change as well as autonomic dysfunction (21–23). Similarly, 
individuals with SNCA triplications have early onset rapidly 
progressive parkinsonism and dementia (11). The pathology in 
these cases is characterized by widespread Lewy body not only in 
the brainstem but also in the cortex, as well as neuronal loss in the 
hippocampal CA2/3 region (11, 24). However, SNCA duplication 
leads to PD with a more benign phenotype, similar to idiopathic 
PD (34). In contrast, Parkin-associated PD is a more “pure” motor 
disorder with a very low incidence of dementia. A meta-analysis 
of available phenotypic data in Parkin mutation carriers indicated 
that only 7% of 58 cases carrying 1 mutant allele developed 
dementia over 12 years of follow-up, with incidence rates being 
even lower in those carrying 2 mutant alleles at 1% of 232 cases 
over 19  years (30). This is consistent with neuropathological 
findings in Parkin-associated PD, which indicate that the disease 
is largely restricted to the nigrostriatal tract with the absence of 
Lewy bodies (31). LRRK2 mutations represent the commonest 
cause of autosomal dominantly inherited PD (25), and hence 
the clinical phenotype has been well described, particularly in 
association with the most frequently occurring G2019S muta-
tion. The clinical phenotype is similar to idiopathic PD (26), 
although the prevalence of dementia is reported to be lower 
(27,  28). Most LRRK2 G2019S PD cases have the typical pattern 
of brainstem pathology with Lewy bodies with variable cortical 
involvement, but Lewy bodies are not a universal finding, and 
are present in less than half of those with LRRK2 mutations other 
than G2019S (24), in keeping with the more benign phenotype 
when compared to SNCA-associated PD. Other observed but less 
well-replicated genotype–phenotype associations include a high 
prevalence of psychiatric symptoms in PINK-1 families (32) and 
learning difficulties and cognitive impairment in a Swiss family 
with the D620N mutation in VPS35 causing early onset tremor 
dominant PD (29).
Although these observations are of interest, in general there 
is a paucity of longitudinal data on phenotypic characteristics 
in Mendelian forms of PD. A meta-analysis in 2010 identified 
119 studies reporting information on non-motor symptoms 
in 990 cases with monogenic forms of PD, but the available 
phenotypic data were limited, with dementia frequency being 
reported in only 54% of studies, and most studies did not clearly 
distinguish between point and lifetime prevalence of non-motor 
symptoms, thus making interpretation of their data difficult. 
With these important caveats, the meta-analysis confirmed the 
highest prevalence of dementia among SNCA mutation carriers 
(approximately 25%) and the lowest among Parkin mutation car-
riers (approximately 3%) (35).
Hence, although these monogenic forms provide some insight 
into the pathogenesis of PD dementia, a more systematic evalu-
ation of their phenotypic characteristics is needed to clarify how 
they contribute to the cognitive heterogeneity of PD.
Glucocerebrosidase
Mutations in the glucocerebrosidase gene, GBA, cause the 
autosomal recessive storage disorder Gaucher’s disease, a lyso-
somal storage disorder, but the observation that parkinsonism 
is frequently observed in this disease and in family members 
of Gaucher’s patients (36), in association with Lewy body 
deposition in the brainstem and cortex, led to the recognition 
of an increased frequency of heterozygote GBA mutations in PD 
cases versus controls. These mutations occur even in those with 
seemingly sporadic disease and have now been established as 
the commonest genetic risk factor for PD identified to date (37). 
GBA mutations are estimated to account for around 3–4% of PD 
cases (38, 39) with much higher frequencies of around 15% in 
Ashkenazi Jewish populations (38). However, these mutations 
also occur in around 3% Ashkenazi Jewish individuals and 1% 
of non-Jewish individuals (38, 39), hence their classification as 
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a susceptibility factor for PD rather than a monogenic cause of 
the disease.
There is now clear evidence that GBA-associated PD has a 
more aggressive phenotype than idiopathic PD, particularly in 
terms of progression to dementia. In cross-sectional studies, the 
prevalence of dementia in GBA-PD cases is reported to be around 
50% (39, 40), compared to a dementia prevalence of 24–31% in 
idiopathic PD cases (41), and this difference is particularly strik-
ing given that many GBA-associated cases are young onset (39). 
GBA mutations have also been reported to be associated with a 
younger onset of Dementia with Lewy Bodies, as well as male 
gender (42), although this gender association has not been rep-
licated and, in fact, an opposite gender effect has been reported 
for PD with GBA mutations being more common in women 
(40). Longitudinal studies have confirmed a faster progression 
to dementia in PD cases carrying GBA mutations (43, 44), with 
an odds ratio for dementia of 4.6 (95% CI 1.3–15.9) for GBA-PD 
compared to idiopathic PD in a population-representative cohort 
followed up for 10 years from diagnosis (43). Cognitive deficits 
are also described in patients with Gaucher’s disease and healthy 
carriers of GBA mutations (45, 46) and may be an early indicator 
of neurodegenerative pathology in these cases.
The mechanism underlying this association between GBA 
mutations and PD/PD dementia is still not entirely clear. GBA 
is a lysosomal enzyme responsible for the breakdown of gluco-
sylceramide, resulting in the accumulation of glucosylceramide 
in cells (47). Pathologically, PD-GBA cases are characterized 
by limbic or neocortical Lewy body deposition (48), and colo-
calization of glucocerebrosidase with Lewy bodies in these GBA 
mutation carriers has been demonstrated (49), supporting the 
theory that mutant glucocerebrosidase may contribute directly to 
increased α-synuclein aggregation (50, 51). It has been proposed 
that accumulation of the substrate glucocerebroside in the lyso-
some, due to impaired function of the enzyme, acts as a backbone 
for α-synuclein aggregation. This in turn leads to compromise of 
GBA activity and lysosomal function and a consequent increase in 
α-synuclein aggregation in a positive feedback loop (51). Further 
understanding of these mechanisms may lead to the development 
of novel disease-modifying therapies targeted at GBA to slow 
progression to dementia in PD. However, the overall impact of 
GBA mutations on the incidence of dementia in PD remains low 
given that these mutations account for only 3–4% of PD cases 
(38, 39), and it is unclear how relevant such therapeutic strategies 
might be in idiopathic PD.
Microtubule-Associated Protein Tau
Microtubule-associated protein tau is a protein involved in 
microtubule assembly and stabilization, which forms patho-
logical aggregates in a number of neurodegenerative diseases. The 
gene is encoded on chromosome 17q21 in the center of a 900-kb 
long fragment, which is inverted in a proportion of the popula-
tion due to the divergence of two chromosomal lineages (H1 
and H2) more than 3 million years ago with no recombination 
since (52). The inverted H2 haplotype accounts for approximately 
25% of haplotypes in those with European ancestry. MAPT  
H1/H1 genotype has been firmly established not only as a risk 
factor for tauopathies, including progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD), but also associated 
with increased PD risk (53). Although significant tau pathology is 
not found in the majority of idiopathic PD cases at postmortem, 
there is clear evidence that tau interacts with α-synuclein in Lewy 
body formation. Tau epitopes are found within Lewy bodies on 
immunostaining of PD postmortem brains (54), α-synuclein 
fibrils have been shown to induce polymerization of tau into 
hyperphosphorylated aggregates in  vitro (55), and transgenic 
mice overexpressing α-synuclein have increased levels of 
hyperphosphorylated tau colocalizing with α-synuclein deposits 
(56). Thus, MAPT variation is a good candidate to influence the 
development of dementia in PD given the widespread cortical 
Lewy body deposition which characterizes this state.
Association between the MAPT H1/H1 genotype and cogni-
tive dysfunction in PD was first reported in 2007 in a longitu-
dinal study of a population-representative incident PD cohort 
(n =  108): over a mean (SD) follow-up of 3.5 (0.7) years from 
diagnosis, age was strongly correlated with cognitive decline in H1 
homozygotes but cognitive performance remained unchanged in 
H2 carriers, regardless of advancing age. In the same CamPaIGN 
cohort at 5 years from diagnosis, all but one of the PD cases who 
had developed dementia carried the H1/H1 genotype (18/65 
of H1/H1 versus 1/34 of H2 carriers), with an estimated odds 
ratio (with adjustment for age and other confounding factors) 
for dementia of 12.1 (57), strikingly greater than the estimated 
odds ratio for PD susceptibility for MAPT of 1.4 (53), suggesting 
that MAPT H1 has a much more profound influence on cognitive 
function in early PD than on risk of disease per se. The 10-year 
follow-up data from CamPaIGN continued to support an asso-
ciation between H1/H1 genotype and progression to dementia, 
although the magnitude of the effect seems to lessen with increas-
ing disease duration (age-adjusted hazard ratio 2.9) (1). While 
this association has been replicated by other groups, including a 
large case–control study reporting a much stronger association 
with H1 haplotype for PD dementia (OR = 3.73; P = 0.002) than 
for PD without dementia (OR = 1.89; P = 0.04) (58), some studies 
have failed to find such an association (59, 60). The discrepancy 
may reflect the nature of the cohorts assessed, with negative 
associations in prevalent cohorts with longer disease durations, 
suggesting that the predominant effect of the MAPT H1 variant 
may be to accelerate cognitive decline within the early years of 
the disease.
Further support for this concept comes from functional MRI 
studies in patients with early PD, demonstrating association 
between MAPT H1/H1 and reduced brain activation in medial 
temporal and parietal regions during memory and visuospatial 
tasks, respectively, but no association with frontostriatal function 
(61, 62). Hence, the MAPT H1/H1 effect seems to be specific 
to posterior cortical circuitry, and given the observations that 
posterior cortical deficits predict early dementia in PD (dis-
cussed above), this genetic variant may be a critical driver of this 
dementing pathway (see Figure 1).
Evidence from postmortem studies supports the hypothesis 
that the MAPT H1 variant exerts it phenotypic effects through 
promoting protein aggregation and Lewy body formation. In a 
cohort of 22 dementia with Lewy body cases, total Lewy body 
counts were found to be significantly higher in H1/H1 (n = 12) 
FiGURe 2 | The relationship between working memory (wM) 
performance and dopamine levels in the prefrontal cortex follows an 
inverted U-shaped curve. Behavioral and functional imaging data from PD 
patients indicates that an individual’s position on the curve is dependent on 
their stage of disease as well as their COMT val158met genotype (which 
determines the activity of the COMT enzyme). Hence, the relationship 
between executive function and COMT genotype in PD is complex, and 
executive deficits may improve rather than worsen in certain genotypic 
groups as the disease progresses. Reproduced from Williams-Gray et al. 
(84).
5
Collins and Williams-Gray Cognitive Impairments in Parkinson’s Disease
Frontiers in Psychiatry | www.frontiersin.org May 2016 | Volume 7 | Article 89
versus H2 (n = 10) carriers matched for demographics and clini-
cal variables, with no between-group difference in Alzheimer’s 
type pathology (63). Furthermore, in a large postmortem series 
of cases with Alzheimer’s disease (AD), Lewy body disease or vas-
cular pathology (n = 762), the MAPT H1 variant was associated 
with higher cortical Lewy body counts and reduced Alzheimer’s 
type changes (64). The functional mechanism by which the 
MAPT H1 variant might lead to changes in protein aggregation 
is unknown, but increased expression levels of total tau or of 
four repeat tau isoforms has been reported in PD as well as the 
tauopathies (65–67), and the H1 haplotype is associated with an 
increase in four repeat tau transcription in PD brain (57, 68).
Catechol-O-Methyltransferase
The COMT enzyme is a key regulator of synaptic dopamine 
levels, particularly in the frontal cortex where the dopamine 
transporter (DAT) is rarely expressed (69). The COMT gene 
contains a common functional polymorphism of valine (val) for 
methionine (met) at codon 158, which alters the thermostability 
of the enzyme, resulting in a reduction in activity of 40% in human 
frontal cortex in met versus val homozygotes (70). Healthy sub-
jects with low activity COMT genotypes (met/met, with putatively 
higher prefrontal dopamine levels) show improved performance 
on working memory (WM) and attentional control tasks activat-
ing the prefrontal cortex (71–73). Hence, COMT val158met is a 
good candidate for modulating the frequently observed executive 
deficits in PD, which are known to be mediated by dopaminergic 
dysfunction in frontostriatal networks (74).
This genetic variant has indeed been shown to alter perfor-
mance on such tasks in PD, although the direction of the effect 
is opposite to that seen in controls. Specifically, in a cohort of 
patients with early PD (n = 288), an increase in met alleles (i.e., 
lower COMT activity and putatively higher dopamine levels) was 
associated with impaired performance on the CANTAB one-
touch Tower of London, a planning task dependent on prefrontal 
cortical areas, and the impairment was greatest in patients on 
dopaminergic medications (75). This association between COMT 
val158met and executive function has since been replicated in an 
independent early PD cohort (CamPaIGN study), although the 
effect size was small (57). A further study found evidence of an 
interactive effect of COMT met alleles and dopaminergic medica-
tion on executive performance, although it did not demonstrate 
a main effect of COMT possibly due to insufficient power (76). 
Functional MRI studies further support a role for COMT val-
158met in mediating executive function in PD, demonstrating that 
impaired performance on both planning and attentional control 
tasks in met homozygotes is associated with reduced BOLD 
activation in frontoparietal networks (77, 78), and revealing an 
interaction between genotype and dopaminergic medication 
(62), which has potential implications for planning treatment in 
PD patients with significant executive dysfunction.
The detrimental effect of COMT met alleles on executive 
performance in early PD (in contrast to the positive effect in 
healthy controls) seems likely to relate to an “overload” of dopa-
mine in the prefrontal cortex, which can be further exacerbated 
by dopaminergic medication. This hypothesis is consistent with 
[18F]DOPA-PET studies indicating a hyperdopaminergic state 
in prefrontal areas in early PD (79, 80) (presumably compensat-
ing for nigrostriatal dopamine loss), as well as a more recent 
[18F]-DOPA study indicating that COMT met alleles are associ-
ated with reduced dopamine metabolism and higher synaptic 
dopamine levels in frontal brain regions in early PD patients 
(81). Indeed, it is well established in the animal literature that 
there is an inverted U-shaped relationship between executive 
function and dopamine levels in the frontal cortex, with high 
and low synaptic dopamine levels causing impaired perfor-
mance (82). As PD progresses, dopamine levels in the prefrontal 
cortex decline (83) thus resulting in a shift in position on the 
inverted U-shaped curve, and an alteration in the relationship 
between COMT genotype and executive performance with time 
(Figure 2), which has been demonstrated when comparing sub-
groups of patients with early versus late PD (57). Furthermore, 
longitudinal analysis in the CamPaIGN incident PD cohort 
has shown that executive performance improves in met/met 
individuals over 5  years of disease progression, in contrast to 
other COMT genotypic groups. So, this genetic variant, while 
modulating executive heterogeneity in PD through its effects 
on frontal dopaminergic networks, is not necessarily associated 
with poor cognitive outcomes in PD and, in particular, does not 
appear to be associated with dementia risk (57).
Apolipoprotein e
Association between the APOE gene and susceptibility to AD is 
well established (85). There is an overlap between AD and PD 
both clinically and pathologically: dementia and extrapyramidal 
features occur in both, and neuronal loss and aberrant protein 
aggregation are common pathological features; and hence, a 
possible association of APOE with susceptibility to PD and PD 
dementia has been debated for some time. APOE has three major 
alleles: APOE-ɛ2, APOE-ɛ3, and APOE-ɛ4. APOE-ɛ4 is associated 
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with both AD risk and lower age of onset, whereas APOE-ɛ2 is 
protective (85). The functional basis of these effects is thought to 
be mediated at least in part through altered amyloid metabolism, 
but APOE has also been implicated in the molecular pathway of 
α-synuclein-mediated neurodegeneration (86).
A large meta-analysis of over 4000 cases and 10,000 controls 
has suggested an over-representation of APOE-ɛ2 carriers among 
PD patients compared to controls, although the odds ratio was 
very modest at 1.16 (95% CI 1.03–1.31) (84), and association 
between APOE and PD risk has not been replicated in further 
large scale genetic association studies (87) or genome-wide 
association studies in PD. Further meta-analysis indicated an 
over-representation of APOE-ɛ4 carriers among PD dementia 
cases (n = 501) compared to PD non-dementia cases (n = 1145) 
[OR 1.74 (1.36–2.23)] (84). However, the validity of this finding 
is limited by the small number of PDD cases in each study, the 
significant heterogeneity of odds ratios between studies, and 
evidence of publication bias (84). Perhaps most importantly, such 
cross-sectional studies are probably misleading because any effect 
of APOE-ɛ4 is likely to be time-dependent analogous to its effect 
in AD. Longitudinal analyses should be more informative, but 
only a small number of such studies have been published to date, 
and again findings have been inconsistent.
The effect of APOE-ɛ4 carrier status on longitudinal 
cognitive decline in PD was investigated in the CamPaIGN 
cohort (n =  107) over a 5-year period from diagnosis, and no 
evidence for association with rate of change in MMSE scores, 
age-dependent cognitive decline, or incidence of dementia was 
found (84). Similarly, no associations between APOE genotype 
and development of dementia were found in another incident PD 
cohort (n = 64) followed up for a mean of 9.7 years from diagnosis 
(88). In contrast, a study of 212 PD patients found more rapid 
cognitive decline (Mattis Dementia Rating Scale) over 4  years 
in APOE-ɛ4 carriers compared to non-carriers, but these were 
more advanced cases at study entry with a mean disease duration 
of 7 years (60). In the same study, MAPT H1/H1 genotype was 
not associated with cognitive decline over time, although there 
was an association with memory performance (60). Hence, the 
disparity between studies may reflect the fact that these genetic 
variants have time-dependent effects on cognition which vary 
with disease stage: MAPT seems to have its greatest impact on 
cognitive decline in early PD, whereas APOE may have a more 
pronounced effect in later disease. This raises the question of 
whether association between APOE genotype and dementia in 
PD reflects the development of Alzheimer’s type pathology in 
the aging brain. Indeed, a recent study of 232 PD cases reporting 
association between APOE-ɛ4 and dementia status (OR 5.15) 
found Alzheimer’s type pathology including moderate to high 
frequency neuritic plaques and Braak tau stage ≥3 in 90% of 
APOE-ɛ4 carriers coming to postmortem (n =  10) compared 
to 43–53% of non-carriers (n = 19) (89). However, postmortem 
examination over 900 dementia cases and controls genotyped for 
APOE has demonstrated that APOE-ɛ4 frequency is increased 
not only in cases with pathologically confirmed AD (38.1%) and 
mixed Lewy body-AD pathology (40.6%) but also in those with 
“pure” DLB (31.9%) and “pure” PDD (19.1%) compared to con-
trols (7.2%), indicating that the contribution of APOE-ɛ4 to the 
dementing process in PD is not mediated entirely through effects 
on amyloid metabolism and Alzheimer’s type changes (90).
DiSCUSSiON AND CONCLUSiON
As our knowledge of the genetic basis of PD continues to expand, 
it is becoming increasingly apparent that genetic factors are 
important not only in determining an individual’s susceptibility 
to the disease but also how their disease evolves phenotypically 
(Table 2). Clinical evaluation of cases with Mendelian forms of 
PD has been informative to some extent, in particular, in terms of 
corroborating the importance of α-synuclein in the pathogenesis 
of dementia in PD, but longitudinal data still remains limited in 
many monogenic forms of PD, and more detailed follow-up data 
from these rare cases, ideally with postmortem evaluation, would 
be very valuable. GBA mutations are the most common genetic 
risk factor for PD, and consequently phenotypic data on GBA-PD 
cases are rapidly accumulating, suggesting that these cases have 
an aggressive form of the disease with early onset dementia 
and florid cortical Lewy body pathology. This knowledge has 
prompted a wealth of research into the mechanistic relationship 
between glucocerebrosidase, lysosomal function, and α-synuclein 
aggregation, which may lead to novel therapeutic strategies.
The approach of investigating candidate genes within puta-
tively relevant neurobiological pathways mediating cognitive 
dysfunction in PD is of course inherently biased, but nonethe-
less has yielded some very interesting insights into how cogni-
tive deficits evolve in this disorder, and in particular has helped 
to define distinct cognitive syndromes (57). The frontal dys-
executive syndrome is related to dopaminergic dysfunction in 
frontostriatal networks and modulated by COMT genotype and 
does not necessarily indicate the onset of a dementing process. 
In contrast the posterior cortical syndrome is an age-dependent 
process modulated by MAPT and APOE genotypes, which is 
likely to reflect irreversible protein aggregation and neuronal 
dysfunction in the temporal and parietal cortices, and evolves 
into clinical dementia (Figure 1). Further support for this idea 
of distinct cognitive syndromes in PD has recently come from 
a study which used functional MRI to further interrogate the 
association between COMT, MAPT, and APOE genotypes 
and brain function in the ICICLE-PD cohort of newly diag-
nosed PD patients (n = 168). This study used tasks designed 
to probe executive, visuospatial, and memory domains and 
demonstrated that these three genes had dissociable effects on 
performance in the different cognitive domains associated with 
regionally specific changes in cortical activation. Specifically, 
COMT val158met was found to interact with levodopa dose to 
modulate activation in frontostriatal regions during the execu-
tive task, MAPT H1 versus H2 haplotype-modulated activation 
in parietal regions during the visuospatial task, and APOE 
genotype-modulated activation in temporoparietal regions 
during the memory encoding task (62). This concept of dif-
ferent cognitive syndromes in PD has practical implications in 
term of planning therapy in the clinic, for example, those with a 
predominantly dysexecutive syndrome in early PD may benefit 
from a reduction in dopaminergic therapy, whereas those with 
early posterior cortical deficits warrant close follow-up for an 
TABLe 2 | Genes contributing to cognitive heterogeneity in PD.
Genetic variant Association 
with PD risk
Phenotypic effect Proposed mechanism Reference
GBA mutations Yes More rapid progression to dementia Impaired GBA activity, accumulation of glucocerebroside 
and lysosomal dysfunction, consequent increase in 
α-synuclein aggregation
(39, 40, 43, 
44, 48)
MAPT H1/H2 
hapotype
Yes Faster global cognitive decline and higher dementia 
risk in H1 carriers, particularly in early PD
Increased expression of four repeat tau, increased 
protein aggregation, and Lewy body formation
(1, 57, 58, 
65–67)
COMT val158met 
polymorphism
No Met alleles associated with impaired executive 
function in early PD, though may improve with 
disease progression
Increased prefrontal dopamine levels in met carriers 
leading to “overload” effect
(57, 91)
APOE ɛ4 allele No Higher dementia risk, particularly in later stage PD Altered amyloid metabolism promoting Alzheimer’s 
type pathology but also implicated in “pure” Lewy body 
disease
(60, 84, 
88–90)
7
Collins and Williams-Gray Cognitive Impairments in Parkinson’s Disease
Frontiers in Psychiatry | www.frontiersin.org May 2016 | Volume 7 | Article 89
emerging dementia, with a low threshold for starting anticho-
linesterase inhibitors.
Genetic factors differ not only with respect to the cognitive 
domains that they influence but also in terms of their temporal 
relationship with cognition. The relationship between COMT 
val158met and executive function in PD can vary over time, both 
according to disease stage (and underlying frontal dopamine lev-
els) and secondary to changes in dopaminergic medication (57). 
The dementing process appears to be accelerated in early disease 
by MAPT H1/H1 genotype, although ultimately the same process 
occurs at a delayed rate in H2 carriers (1); hence, studies in later 
disease do not necessarily detect a phenotypic effect. In contrast, 
there is evidence to suggest that APOE genotype is associated 
with the development of dementia in later disease (60), but an 
impact on early dementia in PD has not been demonstrated in 
longitudinal studies (84, 88). This highlights the importance of 
longitudinal rather than cross-sectional studies to gain a true pic-
ture of the relationship between genetic factors and phenotypic 
variation in PD.
The advent of new technologies allowing whole-genome inves-
tigations, such as genome-wide association studies (GWAS) and 
whole-exome sequencing of large cohorts, has led to the recent 
discovery of a number of new unanticipated genetic loci associ-
ated with PD. These include signal-induced proliferation-asso-
ciated 1 like 2 (SIPA1L2), inositol polyphosphate-5-phosphatase 
F (INPP5F), microRNA 4697 (MIR4697), GTP cyclohydrolase 
(GCH1), vacuolar protein sorting 13 homolog C (VPS13C), and 
DDRGK domain containing 1 (DDRGK1) (9). However, the 
contribution of genetic variation at these loci to the clinical and 
cognitive heterogeneity of PD is yet to be explored. Given that 
the contribution of individual genetic variants may be small, the 
optimal strategy for the future will be to pool genetic datasets 
with longitudinal clinical data from multiple centers to provide 
sufficient power to adequately interrogate genotypic–phenotypic 
associations. Ultimately, detailed genetic profiling may provide us 
with a reliable tool for stratification of cognitive prognosis in PD, 
which will be invaluable for the selection of the most appropriate 
patients for future trials of therapies to prevent dementia in PD, 
as well as to better guide management strategies for this devastat-
ing aspect of the disease. Furthermore, as our understanding of 
the genetic basis of cognitive dysfunction in PD evolves, so will 
our knowledge of the underlying pathophysiological pathways 
involved, with consequent implications for the development of 
novel therapies.
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